Navigation Links
Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
Date:12/7/2008

drome in patients receiving VELCADE. Some of these events have been fatal. There have been reports of Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions. Patients who are concomitantly receiving VELCADE and drugs that are inhibitors or inducers of cytochrome P450 3A4 should be closely monitored for either toxicities or reduced efficacy. Patients on oral antidiabetic medication while receiving VELCADE should check blood sugar levels frequently.

Adverse Reaction Data

Safety data from Phase II and III studies of single-agent VELCADE 1.3 mg/m(2)/dose twice weekly for 2 weeks followed by a 10-day rest period in 1163 patients with previously treated multiple myeloma (N=1008, not including the Phase III, VELCADE plus DOXIL(R) [doxorubicin HCl liposome injection] study) and previously treated mantle cell lymphoma (N=155) were integrated and tabulated. In these studies, the safety profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma.

In the integrated analysis, the most commonly reported adverse events were asthenic conditions (including fatigue, malaise and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and peripheral neuropathy aggravated)
'/>"/>

SOURCE Millennium: The Takeda Oncology Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... 1, 2014 Reportbuyer.com has added a ... Aesthetic Lasers and Energy Devices Market Outlook to ... Brazil Aesthetic Lasers and Energy Devices ... GlobalData,s new report, "Brazil Aesthetic Lasers ... key market data on the Brazil Aesthetic Lasers ...
(Date:9/1/2014)... Sept. 1, 2014 Reportbuyer.com has ... Rigid Transparent Plastics: Global Markets Outside ... INTRODUCTION This chapter provides ... the study goals and objectives, reasons for ... information sources and analyst credentials, and related ...
(Date:8/30/2014)... , Aug. 30, 2014   Royal Philips  (NYSE: ... Affiniti, a new ultrasound system designed to enable ... of increasing patient volumes and cost pressures. Making its ... in Barcelona this week, ... more patients with fewer resources deliver high quality patient ...
Breaking Medicine Technology:Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 9Rigid Transparent Plastics: Global Markets Outside North America 2Rigid Transparent Plastics: Global Markets Outside North America 3Rigid Transparent Plastics: Global Markets Outside North America 4Rigid Transparent Plastics: Global Markets Outside North America 5Rigid Transparent Plastics: Global Markets Outside North America 6Rigid Transparent Plastics: Global Markets Outside North America 7Rigid Transparent Plastics: Global Markets Outside North America 8Rigid Transparent Plastics: Global Markets Outside North America 9Rigid Transparent Plastics: Global Markets Outside North America 10Rigid Transparent Plastics: Global Markets Outside North America 11Rigid Transparent Plastics: Global Markets Outside North America 12Rigid Transparent Plastics: Global Markets Outside North America 13Rigid Transparent Plastics: Global Markets Outside North America 14Rigid Transparent Plastics: Global Markets Outside North America 15Rigid Transparent Plastics: Global Markets Outside North America 16Rigid Transparent Plastics: Global Markets Outside North America 17Rigid Transparent Plastics: Global Markets Outside North America 18Rigid Transparent Plastics: Global Markets Outside North America 19Rigid Transparent Plastics: Global Markets Outside North America 20Rigid Transparent Plastics: Global Markets Outside North America 21Rigid Transparent Plastics: Global Markets Outside North America 22Rigid Transparent Plastics: Global Markets Outside North America 23Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4
... CITY, Calif., Feb. 23, 2011 Abaxis, Inc. (Nasdaq: ... analysis systems, announced today that Clint Severson, chairman and chief ... Conference on Thursday, March 3, 2011 at 10:00 a.m. ET. ... Hotel in New York City. A live webcast ...
... Foundation and Vertex Pharmaceuticals announced today that VX-770, an oral ... cystic fibrosis, showed promising results in a Phase 3 clinical ... patients age 12 and up who carry at least one ... 161 patients who received at least one dose of VX-770 ...
Cached Medicine Technology:Abaxis, Inc. to Present at RBC Capital Markets' Healthcare Conference 2Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation 2Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation 3
(Date:9/2/2014)... (PRWEB) September 02, 2014 Lseat.com is one ... covers . All its products are user-friendly items; no professional ... original seat covers; they can slip right over the cars’ ... Now, the company’s website is filled with various kinds of ... its new designs of Jeep leather seat covers . ...
(Date:9/2/2014)... MA (PRWEB) September 02, 2014 A ... for everyone. But sometimes the onset of irritability, sadness, ... condition, reports the September 2014 Harvard Health Letter. ... response to everyday stresses. If they occur for long ... it's an indication to seek help," says Dr. Nancy ...
(Date:9/2/2014)... September 02, 2014 Researchers in New Delhi, ... developed mesothelioma after being exposed to asbestos-contaminated work clothes for ... the details of the report in a new article. ... the ESI Model Hospital say their patient was diagnosed ... Further investigation found that she had come in contact with ...
(Date:9/2/2014)... 2014 Eric Jimenez and Leah Ashley ... a revolutionary makeup application device. Designed to improve and ... in the palm of women’s hands to help them ... Color Me’s success lies in its patented technology. With ... of 15,000 pulses per minute, the device applies foundation ...
(Date:9/2/2014)... 2014 Innovations Television, produced by ... content for upcoming episodes of Innovations, focusing on ... 2015. , Innovations, hosted by Ed Begley, Jr., ... breakthroughs and advancements taking place in all areas ... advancements in biosciences. Biosciences are at the core ...
Breaking Medicine News(10 mins):Health News:High Quality 1997-2006 JEEP Wrangler TJ Leather Seat Covers From Popular Supplier Lseat.com 2Health News:When a Mood Swing Signals Trouble, From the September 2014 Harvard Health Letter 2Health News:New Report Illustrates That Even Brief Asbestos Exposure Can Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 3Health News:Exciting New Episodes of Innovations with Ed Begley Jr to Air via Discovery Channel 2
... Ill., May 13 Z Trim Holdings, Inc.,(Amex: ... statements,for the fiscal year ended December 31, 2007 contained ... accounting,firm, Blackman Kallick LLP. This announcement is being made ... which requires separate disclosure,of receipt of an audit opinion ...
... today signed three bills into law:, Senate Bill ... pharmacies, under the supervision of the State Board of,Pharmacy, ... Under the program, drugs may be returned to an ... their original packaging and the,drug expires no sooner than ...
... Company Management to discuss the benefits of Hemodiafiltration therapy and ... of Life for End-Stage Renal Disease Patients, NEW YORK, ... device company developing and marketing products designed to,improve the quality ... the critical financial and clinical needs of the care,provider, today ...
... May 13 eDiets.com,Inc. (Nasdaq: DIET ), leveraging ... healthy lifestyle solutions to everyone, today announced,results for the ... first quarter of 2008 were $8.8 million, compared to,$8.4 ... for the quarter,was $(5.1) million, or $(0.20) per diluted ...
... heres another reason to encourage your daughters to be physically ... ages of 12 and 35 have a substantially lower risk ... less active, new research shows. , In the largest ... exercise on premenopausal breast cancer, the study of nearly 65,000 ...
... underwent circulatory procedure , , TUESDAY, May 13 (HealthDay ... that the clot-preventing drug Plavix could help in the ... suitable for dialysis for kidney patients. , Giving Plavix ... would block the vessel created by combining a vein ...
Cached Medicine News:Health News:Z Trim Holdings, Inc. Audit Report Contains 'Going Concern' Qualification 2Health News:Nephros Exhibits at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008 2Health News:Nephros Exhibits at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008 3Health News:Nephros Exhibits at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008 4Health News:eDiets.com(R) Announces Q1 2008 Results 2Health News:eDiets.com(R) Announces Q1 2008 Results 3Health News:eDiets.com(R) Announces Q1 2008 Results 4Health News:eDiets.com(R) Announces Q1 2008 Results 5Health News:eDiets.com(R) Announces Q1 2008 Results 6Health News:Girls, young women can cut risk of early breast cancer through regular exercise 2Health News:Blood-Thinner No Help for Dialysis Treatment 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: